logo
Share SHARE
FONT-SIZE Plus   Neg

Shire Reaffirms Support Of Patients Requiring Midodrine HCl - Quick Facts

Shire plc (SHPGY,SHP.L) said that it reaffirmed its commitment to patients as set forth in its recent agreement with the Center for Drug Evaluation and Research or CDER at the U.S. Food and Drug Administration (FDA) to conduct two additional clinical trials to verify and describe the clinical benefit of midodrine HCI.

Midodrine HCl, approved in 1996 under Subpart H (an accelerated approval process) for the treatment of symptomatic orthostatic hypotension (SOH), will remain available to patients who rely on this medicine while Shire's trials are conducted.

"Our agreement is especially important in light of the recent FDA Complete Response Letter for the New Drug Application (NDA) for droxidopa, a competitor investigational product, for the treatment of symptomatic neurogenic orthostatic hypotension in certain patient types. We appreciate the FDA's agreement to keep midodrine HCI on the market while we conduct the agreed upon trials," said Jeffrey Jonas, M.D., Senior Vice President of Research & Development for Shire.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sarah Palin, former Alaska governor and vice-presidential candidate, filed a defamation lawsuit against The New York Times Co. on Tuesday for the alleged defamation in a recent editorial. In the lawsuit, which was filed in the United States District Court for the Southern District of New York, Palin stated that the editorial falsely portrayed her as responsible for inciting the 2011 shooting of D Dutch consumer electronics giant Philips Electronics NV Wednesday announced a definitive merger agreement to buy Spectranetics Corp., a vascular intervention and lead management solutions provider. Under the deal, Philips will commence a tender offer to buy Spectranetics for $38.50 per share, to be paid in cash upon completion. The implied enterprise value is approximately 1.9 billion euros. Samsung Electronics Co. is reviving its Galaxy Note 7 premium smartphone, which was recalled last year over faulty battery issues. A refurbished version of the smartphone with different components under the name Galaxy Note 7 Fandom Edition or FE will be coming to retailers' shelves on July 7, reports said.
comments powered by Disqus
Follow RTT